The France myasthenia gravis treatment market is anticipated to witness significant growth due to presence of massive pool of health-conscious consumers during the forecast period. Other major factors driving the growth of market are increase in prevalence of myasthenia gravis and rise in awareness regarding early diagnosis & adoption of novel treatment options for myasthenia gravis.
Further, the myasthenia gravis treatment market is expected to witness significant growth owing to rise in focus of pharmaceutical companies on the development of novel drugs for the treatment of the disease. In addition, several drugs, including monoclonal antibodies and immunosuppressants, are being developed & tested for their efficacy in treating myasthenia gravis. Moreover, increase in investment in R&D by pharmaceutical companies is expected to intensify the market growth. Furthermore, rise in awareness about myasthenia gravis among patients & healthcare professionals is contributing to rise in demand for its treatments. Further, as more people are gaining awareness regarding the symptoms & risks associated with myasthenia gravis, they are opting for early diagnosis & treatment.
Moreover, government initiatives to improve healthcare infrastructure & increase awareness about myasthenia gravis are driving the market growth. The market growth is further expected to be driven due to the availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of autoimmune diseases, and surge in demand for novel drugs for the management of myasthenia gravis. In addition, various organizations along with the government are counseling people regarding autoimmune diseases. Furthermore, numerous animations through health apps to educate people regarding myasthenia gravis & usage of medications have contributed toward the market growth. Further, rise in demand for effective intravenous immunoglobulin and monoclonal antibodies is expected to strengthen the development of the market. Moreover, increase in promotional activities by manufacturers is expected to fuel the market growth in the near future.
However, the myasthenia gravis treatment market is challenged by several restraints. The major restraint for the growth of the France myasthenia gravis treatment market are the side effects associated with the drugs used for the treatment of the disease. In addition, drugs such as corticosteroids and immunosuppressants are associated with several side effects, including increased risk of infection, weight gain, mood changes, & gastrointestinal problems, which can impact patient compliance further hampering the market growth. Moreover, the outbreak of COVID-19 has disrupted workflows in the healthcare sector of the France. The delay in diagnosis & treatment of myasthenia gravis during the pandemic had a significant impact on patient outcomes. During that time, patients with non-emergency conditions such as myasthenia gravis were unable to receive timely medical attention. This delay in diagnosis & treatment has led to disease progression and worsened symptoms, impacting the quality of life of myasthenia gravis patients.
Moreover, the pandemic disrupted the supply chains of drugs & medical devices in the France market, leading to shortages & delays in delivery of myasthenia gravis treatments. In addition, companies operating in the myasthenia gravis treatment market were impacted financially by the pandemic, with revenue growth being limited owing to supply chain issues. It has further increased the risk of myasthenic crisis, respiratory failure, and permanent pulmonary damage in myasthenia gravis patients due to their suppressed immune systems.
The myasthenia gravis treatment market is segmented into drug class, age group, and distribution channel. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin, and others. By age group, the market is segregated into below 55 years and above 55 years. Depending on the distribution channel, the market is divided into hospital pharmacies, drug stores, retail pharmacies & online providers.
Key players in the France myasthenia gravis treatment market are Sanofi, Merck KGaA, Mylan, Caremark, UCB Pharma, Teva Pharmaceuticals, Novartis, Abbott Laboratories, Eli Lilly, OBS Medical.
It analyzes the key strategies adopted by major market players in the France myasthenia gravis treatment market.
The study assesses and ranks the top factors that are expected to impact the growth of the France myasthenia gravis treatment market.
It identifies the top investment pockets in the market.
Further, the myasthenia gravis treatment market is expected to witness significant growth owing to rise in focus of pharmaceutical companies on the development of novel drugs for the treatment of the disease. In addition, several drugs, including monoclonal antibodies and immunosuppressants, are being developed & tested for their efficacy in treating myasthenia gravis. Moreover, increase in investment in R&D by pharmaceutical companies is expected to intensify the market growth. Furthermore, rise in awareness about myasthenia gravis among patients & healthcare professionals is contributing to rise in demand for its treatments. Further, as more people are gaining awareness regarding the symptoms & risks associated with myasthenia gravis, they are opting for early diagnosis & treatment.
Moreover, government initiatives to improve healthcare infrastructure & increase awareness about myasthenia gravis are driving the market growth. The market growth is further expected to be driven due to the availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of autoimmune diseases, and surge in demand for novel drugs for the management of myasthenia gravis. In addition, various organizations along with the government are counseling people regarding autoimmune diseases. Furthermore, numerous animations through health apps to educate people regarding myasthenia gravis & usage of medications have contributed toward the market growth. Further, rise in demand for effective intravenous immunoglobulin and monoclonal antibodies is expected to strengthen the development of the market. Moreover, increase in promotional activities by manufacturers is expected to fuel the market growth in the near future.
However, the myasthenia gravis treatment market is challenged by several restraints. The major restraint for the growth of the France myasthenia gravis treatment market are the side effects associated with the drugs used for the treatment of the disease. In addition, drugs such as corticosteroids and immunosuppressants are associated with several side effects, including increased risk of infection, weight gain, mood changes, & gastrointestinal problems, which can impact patient compliance further hampering the market growth. Moreover, the outbreak of COVID-19 has disrupted workflows in the healthcare sector of the France. The delay in diagnosis & treatment of myasthenia gravis during the pandemic had a significant impact on patient outcomes. During that time, patients with non-emergency conditions such as myasthenia gravis were unable to receive timely medical attention. This delay in diagnosis & treatment has led to disease progression and worsened symptoms, impacting the quality of life of myasthenia gravis patients.
Moreover, the pandemic disrupted the supply chains of drugs & medical devices in the France market, leading to shortages & delays in delivery of myasthenia gravis treatments. In addition, companies operating in the myasthenia gravis treatment market were impacted financially by the pandemic, with revenue growth being limited owing to supply chain issues. It has further increased the risk of myasthenic crisis, respiratory failure, and permanent pulmonary damage in myasthenia gravis patients due to their suppressed immune systems.
The myasthenia gravis treatment market is segmented into drug class, age group, and distribution channel. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin, and others. By age group, the market is segregated into below 55 years and above 55 years. Depending on the distribution channel, the market is divided into hospital pharmacies, drug stores, retail pharmacies & online providers.
Key players in the France myasthenia gravis treatment market are Sanofi, Merck KGaA, Mylan, Caremark, UCB Pharma, Teva Pharmaceuticals, Novartis, Abbott Laboratories, Eli Lilly, OBS Medical.
Key Benefits For Stakeholders
The report highlights the market analysis based on current trends and future estimations.It analyzes the key strategies adopted by major market players in the France myasthenia gravis treatment market.
The study assesses and ranks the top factors that are expected to impact the growth of the France myasthenia gravis treatment market.
It identifies the top investment pockets in the market.
- Top Player positioning provides a clear understanding of the present position of market players.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Age group
- Below 55 years
- Above 55 years
By Drug class
- Monoclonal antibodies
- Intravenous immunoglobulin
- Others
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers
- Key Market Players
- Sanofi
- Merck KGaA
- Mylan
- Caremark
- UCB Pharma
- Teva Pharmaceuticals
- Novartis
- Abbott Laboratories
- Eli Lilly
- OBS Medical
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
CHAPTER 5: FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
CHAPTER 6: FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Sanofi
- Merck KGaA
- Mylan
- Caremark
- UCB Pharma
- Teva Pharmaceuticals
- Novartis
- Abbott Laboratories
- Eli Lilly
- OBS Medical
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
